DSNKY - Daiichi Sankyo Co., Ltd.

Global leader in ADC technology with the DXd platform. Enhertu is transforming HER2+ cancer treatment and expanding into HER2-low. Deep pipeline of 7 ADCs targeting multiple tumor types. 50/50 partnership with AstraZeneca provides global commercial reach.

Bull Case

Enhertu peak sales $15B+, multiple ADCs reach blockbuster status (Dato-DXd, HER3-DXd), platform validates across targets. Japan specialty portfolio provides stable cash flows.

Bear Case

ADC competition intensifies, safety signals emerge, AZN partnership economics limit upside. Lixiana patent cliff impacts profitability.

Lixiana APPROVED

100% ownership

CVRM Small molecule ORAL

Datroway APPROVED

50% ownership

Oncology ADC IV

Patritumab deruxtecan PHASE3

50% ownership

Oncology ADC IV

Ifinatamab deruxtecan PHASE3

50% ownership

Oncology ADC IV

Enhertu APPROVED

50% ownership

Oncology ADC IV

Vanflyta APPROVED

100% ownership

Oncology Small molecule PO

Drug	Stage	Role	Ownership	Area	Modality
DS-3939	PHASE1	ORIGINATOR	100%	Oncology	ADC
Raludotatug deruxtecan	PHASE2	ORIGINATOR	50%	Oncology	ADC

Period	Revenue ($M)	Gross Margin	R&D	SG&A	Op Income	Op Margin	Net Income	EPS
2024A	$10,773	72.2%	$2,067	$3,467	$2,240	20.8%	$1,520	$2.40
2025E	$12,333	73.0%	$2,333	$3,867	$2,800	22.7%	$2,000	$3.15
2026E	$14,000	73.3%	$2,667	$4,133	$3,467	24.8%	$2,467	$3.90
2027E	$16,000	73.3%	$3,000	$4,533	$4,200	26.3%	$3,000	$4.75
2028E	$18,000	73.3%	$3,333	$4,867	$5,000	27.8%	$3,600	$5.70

Quarter	Revenue ($M)	Gross Margin	Op Margin	EPS
Q4 2025	$3,067	72.8%	22.4%	$0.70
Q3 2025	$3,267	72.4%	23.5%	$0.90
Q2 2025	$3,133	72.3%	22.8%	$0.85
Q1 2025	$2,867	72.1%	19.8%	$0.70

Datroway - TROP2 Biomarker-Directed - Ph3 - Start (TROPION-Lung17)

CLINICAL

DSNKY PR Jan 13, 2026 Jan 2026

Enhertu + Pertuzumab - 1L HER2+ mBC - FDA Approval (DESTINY-Breast09)

REGULATORY SM

FDA Priority Review, daiichisankyo.com PDUFA date Jan 23, 2026

Datroway - 1L mTNBC (PD-L1 neg) - FDA Approval

REGULATORY SM

AstraZeneca/Daiichi Sankyo PR Jan 2026 Q2 2026

DSNKY - 6th 5-Year Business Plan Briefing

CORPORATE SM

daiichisankyo.com Q3 FY2025 Earnings announcement Apr 7, 2026

I-DXd - SCLC - Ph3 - Clinical Hold Update (IDeate-Lung02)

CLINICAL SM

FDA partial clinical hold Dec 2025, FierceBiotech 2026

Enhertu - Global Sales Trajectory

COMMERCIAL

DSNKY Q3 FY2025 Earnings 2026

Datroway + Imfinzi - 1L NSCLC - Ph3 - Topline (AVANZAR)

CLINICAL SM

DSNKY Q3 FY2025 Earnings, ClinicalTrials.gov NCT05687266 H2 2026

Datroway + Keytruda - 1L NSCLC PD-L1 High - Ph3 - Topline (TROPION-Lung08)

CLINICAL SM

DSNKY Q3 FY2025 Earnings, ClinicalTrials.gov NCT05215340 H2 2026

R-DXd - Platinum-Resistant Ovarian - Ph2/3 - Updates (REJOICE-Ovarian01)

CLINICAL

daiichisankyo.com ESMO 2025, ClinicalTrials.gov 2026

Lixiana - Patent Expiration Preparation

COMPETITIVE

DSNKY investor presentations Ongoing

Datroway + Keytruda - 1L NSCLC PD-L1 Low - Ph3 - Topline (TROPION-Lung07)

CLINICAL SM

DSNKY Q3 FY2025 Earnings, ClinicalTrials.gov NCT05555732 H2 FY2026

Underappreciated Risk: AZN Partnership Economics Limiting Value Capture

Bull

AZN provides global commercial infrastructure DSNKY could not build alone. Faster market access = faster revenue ramp. DSNKY retains Japan exclusivity. The partnership enabled Enhertu's rapid global launch.

Bear

DSNKY gets 50% of Enhertu ($15B peak = $7.5B to DSNKY), 50% of Dato-DXd ($5B peak = $2.5B), 50% of I3-DXd ($4B peak = $2B), 50% of patritumab ($3B peak = $1.5B). Total partnership drugs: ~$27B peak, but DSNKY captures ~$13.5B. If DSNKY owned these outright, the value capture would be dramatically higher. The Lixiana patent cliff ($2.3B) compounds the problem — DSNKY needs the ADC franchise to offset, but receives only half the economics.

Conviction: 5/5

Underappreciated Growth Driver: DXd Platform Validation Across New Targets

Bull

Enhertu (HER2) proved the DXd linker-payload. Dato-DXd/Datroway (TROP2) is the second validation. Ifinatamab deruxtecan (HER3-DXd, $4B peak), patritumab deruxtecan (HER3, $3B peak), and R-DXd are all in Phase 3. If 2-3 more DXd-ADCs succeed, the platform becomes the most validated ADC technology in the industry. Each success de-risks the next. DS-3939 (undisclosed target) adds further optionality. Cumulative peak across all DXd-ADCs could exceed $30B.

Bear

ADC competition is intensifying — every major pharma has an ADC program. The DXd payload may not be best-in-class for all targets. Toxicity profiles (ILD risk) may limit broader use. 50/50 AZN partnership means DSNKY captures only half of the largest programs.

Conviction: 5/5

Would change view: SOTP models price each pipeline ADC at 30-50% probability. But platform validation should increase these probabilities — success in HER2 + TROP2 + HER3 means the linker-payload works broadly, raising the prior for each subsequent target.